Krogh, Henriette W.
Svendsen, Karianne
Igland, Jannicke
Mundal, Liv J.
Holven, Kirsten B.
Bogsrud, Martin P.
Leren, Trond P.
Retterstøl, Kjetil
Funding for this research was provided by:
South-Eastern Norway Regional Health Authority
Universitetet i Oslo
Throne-Holst Foundation
Article History
Received: 11 September 2019
Accepted: 8 November 2019
First Online: 17 December 2019
Competing interests
: M.Sc., Krogh, Dr. Igland, Dr. Mundal and Dr. Leren declare no competing interests. Dr. Svendsen reports grants from Mills DA (Vita hjertego’) and a pharmacy interest organization (Stiftelsen til fremme av norsk apotekfarmasi) and personal fees from California Walnut Commission and MedXplore, outside the submitted work. Dr. Bogsrud reports personal fees from Amgen, Sanofi-Aventis, Bristol-Myers Squibb and grants from Kaneka, Mills DA, outside the submitted work. Professor Holven reports grants from Tine SA, Mills DA, Olympic Seafood, Kaneka grants and personal fees from Amgen and personal fees from Sanofi and personal fees from Pronova, outside the submitted work. Professor Retterstøl reports personal fees from Amgen, Mills DA, The Norwegian Directorate of Health, Sanofi, Takeda, Chiesi, Bayer, MSD, MedXplore, Sunnovion and other from The Norwegian Medical Association outside the submitted work.